Patients with serial SEGA growth from pre-baseline to baseline scans were randomly assigned ( 2:1 ) to receive 4.5 mg/m ( 2 ) / day everolimus ( target blood trough : 5-15 ng/mL ; n = 78 ) or placebo ( n = 39 ) .